Savior Lifetec (4167) - Net Assets
Based on the latest financial reports, Savior Lifetec (4167) has net assets worth NT$3.78 Billion TWD (≈ $119.12 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.18 Billion ≈ $131.82 Million USD) and total liabilities (NT$403.30 Million ≈ $12.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Savior Lifetec to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.78 Billion |
| % of Total Assets | 90.36% |
| Annual Growth Rate | 7.84% |
| 5-Year Change | 14.13% |
| 10-Year Change | 78.4% |
| Growth Volatility | 16.57 |
Savior Lifetec - Net Assets Trend (2011–2025)
This chart illustrates how Savior Lifetec's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Savior Lifetec for the complete picture of this company's asset base.
Annual Net Assets for Savior Lifetec (2011–2025)
The table below shows the annual net assets of Savior Lifetec from 2011 to 2025. For live valuation and market cap data, see market value of Savior Lifetec.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.78 Billion ≈ $119.12 Million |
+7.53% |
| 2024-12-31 | NT$3.52 Billion ≈ $110.78 Million |
+4.50% |
| 2023-12-31 | NT$3.36 Billion ≈ $106.01 Million |
-0.07% |
| 2022-12-31 | NT$3.37 Billion ≈ $106.08 Million |
+1.63% |
| 2021-12-31 | NT$3.31 Billion ≈ $104.37 Million |
-0.52% |
| 2020-12-31 | NT$3.33 Billion ≈ $104.92 Million |
+50.43% |
| 2019-12-31 | NT$2.21 Billion ≈ $69.75 Million |
+19.30% |
| 2018-12-31 | NT$1.86 Billion ≈ $58.47 Million |
-14.20% |
| 2017-12-31 | NT$2.16 Billion ≈ $68.15 Million |
+2.07% |
| 2016-12-31 | NT$2.12 Billion ≈ $66.77 Million |
+33.13% |
| 2015-12-31 | NT$1.59 Billion ≈ $50.15 Million |
+23.07% |
| 2014-12-31 | NT$1.29 Billion ≈ $40.75 Million |
-7.23% |
| 2013-12-31 | NT$1.39 Billion ≈ $43.93 Million |
+9.37% |
| 2012-12-31 | NT$1.27 Billion ≈ $40.16 Million |
-2.94% |
| 2011-12-31 | NT$1.31 Billion ≈ $41.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Savior Lifetec's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 75240600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$507.95 Million | 13.44% |
| Other Components | NT$3.27 Billion | 86.56% |
| Total Equity | NT$3.78 Billion | 100.00% |
Savior Lifetec Competitors by Market Cap
The table below lists competitors of Savior Lifetec ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Power Plasma Co.Ltd
KQ:144960
|
$185.38 Million |
|
Lucky Cement Co
TW:1108
|
$185.53 Million |
|
Midnight Sun Mining Corp
V:MMA
|
$185.54 Million |
|
BayWa AG vNa
XETRA:BYW6
|
$185.56 Million |
|
Barings Participation Investors (the Trust)
NYSE:MPV
|
$185.28 Million |
|
Bossa Ticaret ve Sanayi Isletmeleri TAS
IS:BOSSA
|
$185.26 Million |
|
Dynamix Corporation Class A Ordinary Shares
NASDAQ:DYNX
|
$185.26 Million |
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
$185.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Savior Lifetec's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,508,095,000 to 3,779,973,000, a change of 271,878,000 (7.8%).
- Net income of 537,449,000 contributed positively to equity growth.
- Dividend payments of 126,960,000 reduced retained earnings.
- Share repurchases of 138,579,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$537.45 Million | +14.22% |
| Dividends Paid | NT$126.96 Million | -3.36% |
| Share Repurchases | NT$138.58 Million | -3.67% |
| Other Changes | NT$-32.00K | -0.0% |
| Total Change | NT$- | 7.75% |
Book Value vs Market Value Analysis
This analysis compares Savior Lifetec's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.92x to 1.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | NT$9.86 | NT$18.95 | x |
| 2012-12-31 | NT$8.73 | NT$18.95 | x |
| 2013-12-31 | NT$8.34 | NT$18.95 | x |
| 2014-12-31 | NT$7.19 | NT$18.95 | x |
| 2015-12-31 | NT$8.00 | NT$18.95 | x |
| 2016-12-31 | NT$8.56 | NT$18.95 | x |
| 2017-12-31 | NT$8.32 | NT$18.95 | x |
| 2018-12-31 | NT$7.13 | NT$18.95 | x |
| 2019-12-31 | NT$8.16 | NT$18.95 | x |
| 2020-12-31 | NT$9.89 | NT$18.95 | x |
| 2021-12-31 | NT$10.43 | NT$18.95 | x |
| 2022-12-31 | NT$10.57 | NT$18.95 | x |
| 2023-12-31 | NT$9.90 | NT$18.95 | x |
| 2024-12-31 | NT$11.05 | NT$18.95 | x |
| 2025-12-31 | NT$12.18 | NT$18.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Savior Lifetec utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.22%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 44.72%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.11x
- Recent ROE (14.22%) is above the historical average (-8.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -17.86% | -29.83% | 0.34x | 1.78x | NT$-365.90 Million |
| 2012 | -35.52% | -54.05% | 0.35x | 1.87x | NT$-580.31 Million |
| 2013 | -16.40% | -22.86% | 0.36x | 1.98x | NT$-368.13 Million |
| 2014 | -27.51% | -34.92% | 0.33x | 2.42x | NT$-485.13 Million |
| 2015 | -31.02% | -44.06% | 0.35x | 2.04x | NT$-652.98 Million |
| 2016 | -9.80% | -13.56% | 0.45x | 1.62x | NT$-419.62 Million |
| 2017 | 1.03% | 1.38% | 0.41x | 1.83x | NT$-194.03 Million |
| 2018 | -19.37% | -32.55% | 0.31x | 1.90x | NT$-545.12 Million |
| 2019 | -1.99% | -3.34% | 0.33x | 1.82x | NT$-265.43 Million |
| 2020 | 7.54% | 13.73% | 0.38x | 1.45x | NT$-82.08 Million |
| 2021 | -0.14% | -0.27% | 0.38x | 1.37x | NT$-336.05 Million |
| 2022 | 0.61% | 1.63% | 0.29x | 1.32x | NT$-314.63 Million |
| 2023 | 0.90% | 2.86% | 0.27x | 1.14x | NT$-305.24 Million |
| 2024 | 5.20% | 14.98% | 0.28x | 1.25x | NT$-168.43 Million |
| 2025 | 14.22% | 44.72% | 0.29x | 1.11x | NT$159.45 Million |
Industry Comparison
This section compares Savior Lifetec's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,782,670,400
- Average return on equity (ROE) among peers: 2.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Savior Lifetec (4167) | NT$3.78 Billion | -17.86% | 0.11x | $185.34 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more